Mechanical Circulatory Support Devices

Global Mechanical Circulatory Support Devices Market to Reach US$1.4 Billion by 2030

The global market for Mechanical Circulatory Support Devices estimated at US$1.2 Billion in the year 2024, is expected to reach US$1.4 Billion by 2030, growing at a CAGR of 3.1% over the analysis period 2024-2030. Ventricular Assist Devices, one of the segments analyzed in the report, is expected to record a 2.3% CAGR and reach US$648.0 Million by the end of the analysis period. Growth in the Extracorporeal Membrane Oxygenation segment is estimated at 4.4% CAGR over the analysis period.

The U.S. Market is Estimated at US$319.2 Million While China is Forecast to Grow at 5.7% CAGR

The Mechanical Circulatory Support Devices market in the U.S. is estimated at US$319.2 Million in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$274.7 Million by the year 2030 trailing a CAGR of 5.7% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.3% and 2.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.7% CAGR.

Global Mechanical Circulatory Support Devices Market – Key Trends & Drivers Summarized

Why Are Mechanical Circulatory Support Devices Revolutionizing Heart Failure Treatment?

Mechanical circulatory support (MCS) devices are life-saving technologies designed to support or replace the pumping function of the failing heart in patients with advanced heart failure. These devices—including ventricular assist devices (VADs), total artificial hearts (TAHs), and extracorporeal membrane oxygenation (ECMO) systems—are used as bridge-to-transplant, bridge-to-recovery, or destination therapy in cases where pharmacologic management is no longer sufficient. They play a crucial role in improving survival rates, stabilizing patients during critical periods, and enhancing quality of life for those awaiting cardiac transplants or managing irreversible cardiac decline.

Advances in miniaturization, biocompatibility, and long-term implantability have expanded the indications for MCS use across age groups and comorbidities. For end-stage heart failure patients ineligible for transplant, MCS devices offer a viable long-term treatment option that sustains circulatory function and improves mobility and independence. The increasing prevalence of heart failure due to aging populations, ischemic heart disease, and cardiomyopathies is driving the global clinical demand for MCS technologies.

How Are Engineering Advances and Clinical Integration Enhancing Device Utility?

Recent innovations in mechanical and materials engineering have led to the development of next-generation VADs that are smaller, more durable, and less prone to complications like thrombosis, bleeding, or infection. Continuous-flow pumps, magnetically levitated impellers, and wireless energy transfer systems are redefining patient outcomes by improving hemodynamic stability with reduced surgical burden. Wearable driveline systems and fully implantable prototypes are improving patient mobility and quality of life, facilitating outpatient management and long-term use.

On the clinical front, integration of real-time hemodynamic monitoring, remote telemetry, and AI-assisted data interpretation is enhancing decision-making and post-implantation care. Multidisciplinary heart failure teams, including surgeons, cardiologists, and rehabilitation specialists, are implementing patient-tailored MCS protocols supported by advanced imaging and risk stratification tools. These systemic improvements are reducing hospitalization time, improving recovery outcomes, and expanding adoption in tertiary care centers worldwide.

Which Healthcare Settings and Patient Segments Are Leading Adoption?

Cardiothoracic surgical centers, academic hospitals, and advanced heart failure programs are the primary adopters of MCS devices. In the U.S., Europe, and Japan, where cardiac transplant programs are well established, MCS devices are increasingly used as both pre-transplant and destination therapy. Pediatric cardiac centers are adopting miniaturized MCS systems designed for congenital heart disease and pediatric cardiomyopathies, while emerging economies are deploying ECMO systems in critical care units for reversible cardiac or respiratory failure.

Demand is also growing in emergency and trauma settings, where portable ECMO units are deployed to support cardiac arrest patients or bridge critical interventions. Global cardiac surgery programs, especially in high-income nations, are investing in MCS as part of integrated cardiovascular care strategies. As heart failure becomes a leading cause of morbidity and mortality worldwide, demand for mechanical support devices is expected to rise across a broad spectrum of care settings.

The Growth in the Mechanical Circulatory Support Devices Market Is Driven by Several Factors…

The growth in the mechanical circulatory support devices market is driven by increasing prevalence of chronic and end-stage heart failure, advances in device miniaturization, and expanded clinical adoption of VADs and ECMO in transplant and critical care. Rising numbers of patients awaiting heart transplants, coupled with donor organ shortages, are fueling demand for long-term mechanical support. Clinical guidelines are increasingly endorsing early intervention with MCS, while better patient selection and post-discharge protocols are improving outcomes.

Investments in biocompatible materials, wireless power systems, and fully implantable devices are driving innovation, while healthcare systems are allocating resources to heart failure management infrastructure. Emerging applications in pediatric cardiology and trauma care are also creating new use cases. Furthermore, government funding, FDA fast-track designations, and academic-industry partnerships are accelerating product development pipelines—ensuring long-term global market expansion for MCS technologies.

SCOPE OF STUDY:

The report analyzes the Mechanical Circulatory Support Devices market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Product (Ventricular Assist Devices, Extracorporeal Membrane Oxygenation, Intra-Aortic Balloon Pumps, Artificial Heart); End-Use (Hospitals, Cardiology Centers, Ambulatory Surgery Centers, Specialty Centers)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 41 Featured) -

• Abbott Laboratories
• Abiomed, Inc.
• Berlin Heart GmbH
• BiVACOR Inc.
• Braile Biomedica Ltd.
• CardiacAssist, Inc.
• CardioBridge GmbH
• Carmat SA
• Eurosets S.r.l.
• Getinge AB
• Jarvik Heart, Inc.
• LivaNova PLC
• Medtronic plc
• MicroMed Cardiovascular, Inc.
• ReliantHeart, Inc.
• St. Jude Medical, Inc.
• Sun Medical Technology Research Corp.
• SynCardia Systems, LLC
• Teleflex Incorporated
• Terumo Corporation

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA
CHINA
MEXICO
CANADA
EU
JAPAN
INDIA
176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.